Company Overview and News

 
Canada Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

2016-01-07 prnewswire
NEW YORK, Jan. 7, 2016 /PRNewswire/ -- The home health care market includes a wide range of medical devices and...

 
Can Varian's Expanding Product Suite Counter Forex Woes?

2015-12-30 zacks
On Dec 28, we issued an updated research report on Varian Medical Systems (VAR).

 
IDEXX (IDXX) Rides High on International Growth: Invest Now

2015-12-30 zacks
On Dec 29, 2015, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).

 
Plexus Form DEF 14A

2015-12-15 sec.gov
Definitive Proxy Statement Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant  x                            Filed by a Party other than the Registrant  ¨ Check the appropriate box:   ¨   Preliminary Proxy Statement ¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x   Definitive Proxy

 
INVACARE CORP Form 8-K

2015-12-15 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2015 INVACARE CORPORATION (Exact name of Registrant as specified in its charter) Ohio 001-15103 95-2680965 (State or other Jurisdiction of Incorporation or Organization) (Commission File Number) (I.

 
Is Invacare Corporation (IVC) A Good Stock To Buy?

2015-12-13 insidermonkey
Is Invacare Corporation (NYSE:IVC) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because...

 
Haynes International, Inc. (HAYN): Are Hedge Funds Right About This Stock?

2015-12-13 insidermonkey
Insider Monkey finished processing more than 700 13F filings made by hedge funds and prominent investors. These filings show these funds

 
Inogen Form 8-K (Current Report/Significant Event)

2015-12-12 sec.gov
ingn-8k_20151208.htm       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 8‑K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2015   INOGEN, INC. (Exact name of registrant as specified in its charter)     Delaware   001-36309   33-0989359 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.

 
VANGUARD VALLEY FORGE FUNDS Form N-Q

2015-12-01 sec.gov
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-58431   Name of Registrant:   Vanguard Valley Forge Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
VANGUARD INSTITUTIONAL INDEX FUNDS Form N-Q

2015-12-01 sec.gov
institutionalindex_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:    811-06093   Name of Registrant:   Vanguard Institutional Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
ADVANCED SERIES TRUST Form N-Q

2015-12-01 sec.gov
Advanced Series Trust UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES     Investment Company Act file number:      811-05186   Exact name of registrant as specified in charter:      Advanced Series Trust   Address of principal executive offices:      655 Broad Street, 17th Floor, Newark, New Jersey 07102   Name and address of agent for service:      Deborah A.

 
VANGUARD INDEX FUNDS Form N-Q

2015-12-01 sec.gov
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-02652   Name of Registrant:   Vanguard Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
NORTHERN LIGHTS FUND TRUST III Form EX-99.CERT

2015-12-01 sec.gov
Blu Giant, LLC CERTIFICATIONS   I, James P. Ash, certify that:   1. I have reviewed this report on Form N-Q of Cozad Small Cap Value Fund, a Series of the Northern Lights Fund Trust III;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;   3.

 
NORTHERN LIGHTS FUND TRUST III Form N-Q

2015-12-01 sec.gov
Blu Giant, LLC united states securities and exchange commission washington, d.c. 20549 form n-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-22655   Northern Lights Fund Trust III (Exact name of registrant as specified in charter)   17605 Wright Street, Omaha, NE 68130 (Address of principal executive offices) (Zip code)   James Ash, Gemini Fund Services, LLC.

 
RevenueShares ETF Trust Form N-Q

2015-12-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number               811-21993                                                    RevenueShares ETF Trust                                         (Exact name of registrant as specified in charter)   One Commerce Square 2005 Market Street, Suite 2020                                                   

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

8h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...